{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:08:13Z","timestamp":1788566893535,"version":"build-2803163510"},"reference-count":27,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Bcl\u20102 family inhibitors venetoclax and navitoclax demonstrated potent antitumor activity in chronic lymphocytic leukemia patients, notably in reducing marrow load and adenopathy. Subsequent trials with venetoclax have been initiated in non\u2010Hodgkin's lymphoma and multiple myeloma patients. Traditional preclinical models fall short either in faithfully recapitulating disease progression within such compartments or in allowing the direct longitudinal analysis of systemic disease. We show that intravenous inoculation of engineered RS4;11 (acute lymphoblastic leukemia) and Granta 519 (mantle cell lymphoma) bioluminescent reporter cell lines result in tumor engraftment of bone marrow, with additional invasion of the central nervous system in the case of Granta 519. Importantly, apoptosis induction and response of these systemically engrafted tumors to Bcl\u20102 family inhibitors alone or in combination with standard\u2010of\u2010care agents could be monitored longitudinally with optical imaging, and was more accurately reflective of the observed clinical response.<\/jats:p>","DOI":"10.1002\/prp2.178","type":"journal-article","created":{"date-parts":[[2015,9,7]],"date-time":"2015-09-07T09:54:09Z","timestamp":1441619649000},"source":"Crossref","is-referenced-by-count":26,"title":["Clearance of systemic hematologic tumors by venetoclax (Abt\u2010199) and navitoclax"],"prefix":"10.1002","volume":"3","author":[{"given":"Scott","family":"Ackler","sequence":"first","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatol","family":"Oleksijew","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda J.","family":"Chyla","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Clarin","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Foster","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"McGonigal","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasmita","family":"Mishra","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Schlessinger","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morey L.","family":"Smith","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen K.","family":"Tahir","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel D.","family":"Leverson","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Souers","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin R.","family":"Boghaert","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Hickson","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1232-1"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.02048.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-232926"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041720"},{"key":"e_1_2_9_6_1","first-page":"a304","article-title":"The Bcl\u20102\u2010specific BH3\u2010mimetic ABT\u2010199 (GDC\u20100199) is active and well\u2010tolerated in patients with relapsed non\u2010Hodgkin lymphoma: interim results of a phase I study","volume":"120","author":"Davids MS","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_9_7_1","unstructured":"DavidsMS SeymourJF GerecitanoJF KahlBS PagelJM WierdaWM et\u00a0al. (2013)The Bcl\u20102 inhibitor ABT\u2010199 (GDC\u20100199) is active and well tolerated in patients with relapsed\/refractory mantle cell lymphoma and other non\u2010Hodgkin's lymphomas. EHA Congress Abstracts P849."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07835.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2008.10.030"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2009.205"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400555"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0402"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00872.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2911"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21433"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00873.x"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.2656"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm800669s"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7898"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2005.00014.x"},{"key":"e_1_2_9_21_1","first-page":"a872","article-title":"Bcl\u20102 inhibitor ABT\u2010199 (GDC\u20100199) monotherapy shows anti\u2010tumor activity including complete remissions in high\u2010risk relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)","volume":"122","author":"Seymour JF","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3048"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5836"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.6093263"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-173310"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.04110"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature06917"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70261-8"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fprp2.178","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.178","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.178","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T15:55:18Z","timestamp":1696175718000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1002\/prp2.178"],"URL":"https:\/\/doi.org\/10.1002\/prp2.178","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9]]},"article-number":"e00178"}}